AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. - Belmontes B; Slemmons KK; Su C; Liu S; Policheni AN; Moriguchi J; Tan H; Xie F; Aiello DA; Yang Y; Lazaro R; Aeffner F; et al. (Cancer discovery, 2025)